"Enabling Genomics in Routine Medical Care"
To be recognized as the world leader in providing gene expression clinical testing solutions that improve patient care; delivering superior clinical outcomes which reduce the total cost of care.
To develop and deliver proprietary genetic expression diagnostic products that provide critical and actionable clinical information where the understanding of inflammation and host immune response can be used to provide superior personal patient care.
To allow strategic partners access to our proprietary technology enabling the development and delivery of gene expression diagnostic products that provide superior patient care in their areas of expertise.
DxTerity Signs Collaboration Agreement with Caliper Life Sciences read more...
DxTerity Diagnostics Inc. Acquires Gene Signature Portfolio from SourceMDx Inc. read more...
DxTerity Diagnostics receives $244.479 cash grant under QTDP program. read more...
DxTerity wins program with NCI to improve FFPE QC for in situ processing read more...
DxTerity and Duke win 43M Radiation Biodosimetry Contract for National Emergency Response Program. read more...